CureVac to Exit Public Markets Following BioNTech Acquisition

An era has concluded for shareholders of CureVac. The company's shares have ceased trading and will be formally delisted from the Nasdaq, marking the end of its journey as a publicly traded entity. This move finalizes the acquisition by BioNTech, which will now fully integrate the Tübingen-based mRNA specialist's technology.

Trading in CureVac stock was halted prior to market open today, January 6, 2026. This action follows the completion of a post-offer reorganization linked to BioNTech's exchange offer for all outstanding ordinary shares. As a result of this structural measure, CureVac Merger B.V. has replaced CureVac through a merger, with BioNTech now holding 100% ownership of the operational business.

Key outcomes of the finalized deal include:

• The immediate suspension of all public trading in CureVac equity
• The elimination of any remaining public float shareholders
• A scheduled delisting from the Nasdaq, set to become effective on January 16, 2026
• The planned termination of registration with the U.S. Securities and Exchange Commission (SEC), which will take effect 90 days after filing a Form 15

This sequence of events solidifies CureVac's withdrawal from the U.S. capital markets.

A $1.25 Billion Strategic Consolidation

Initially announced in June 2025, the all-stock transaction was valued at approximately $1.25 billion. BioNTech offered its American Depositary Shares (ADS) to CureVac investors as part of the exchange.

Notable details of the acquisition are:

• Transaction Value: $1.25 billion paid in BioNTech ADS
• Exchange Ratio: Roughly $5.46 in BioNTech ADS for each CureVac share
• Tender Rate: A voluntary tender of 86.75% of outstanding shares was achieved
• Acquisition Close Date: December 18, 2025
• Reorganization Completion: January 6, 2026

The remaining shares were acquired through a compulsory acquisition process as part of the now-finalized reorganization, granting BioNTech sole ownership.

Should investors sell immediately? Or is it worth buying CureVac?

Management Transition and Future Integration

Upon the deal's closure, CureVac's entire executive board resigned. BioNTech leadership has assumed control, appointing a new board comprising Prof. Ugur Sahin, M.D., Sierk Poetting, Ph.D., and Ramón Zapata-Gomez.

To ensure operational continuity, CureVac will maintain its existing organizational processes in the near term. Concurrently, BioNTech intends to conduct a strategic, operational, and scientific review of the combined structures and product portfolio to define the future integrated organization.

Merging Pioneering mRNA Expertise

This union brings together two of Germany's early pioneers in mRNA technology. According to company statements, CureVac's expertise complements BioNTech's established strengths in mRNA design, formulations, and manufacturing.

A primary strategic aim of the acquisition is to bolster BioNTech's oncology pipeline. The focus will be on advancing mRNA-based cancer immunotherapies and the bispecific antibody candidate Pumitamig, which is under joint development with Bristol Myers Squibb.

SEC Deregistration Process

CureVac Merger B.V. intends to file a "Certification and Notice of Termination of Registration" on Form 15 with the SEC. This filing will:

• Terminate the registration of CureVac shares under Section 12(g) of the Securities Exchange Act
• Suspend all reporting obligations under Sections 13 and 15(d) of the Act

The suspension of reporting duties is immediate upon filing, with full deregistration expected to become effective 90 days later, based on current plans.

With the delisting and subsequent deregistration, CureVac's chapter as a listed company closes. Its technological assets and development pipeline will henceforth be advanced entirely within BioNTech's broader mRNA platform.